|
Detection of actionable molecular alterations through combined DNA/RNA molecular profiling of biopsies collected in early-stage lung cancer at time of diagnosis. |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Veracyte |
|
|
|
Stock and Other Ownership Interests - Veracyte |
|
|
|
Stock and Other Ownership Interests - Veracyte |
|
|
Consulting or Advisory Role - Johnson & Johnson |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Research Funding - Biodesix (Inst); Veracyte (Inst) |
Travel, Accommodations, Expenses - Auris |
|
|
|
Consulting or Advisory Role - Veracyte |
Speakers' Bureau - Veracyte |
Research Funding - Veracyte (Inst) |
Travel, Accommodations, Expenses - Veracyte |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Auris; Boston Scientific; Olympus |
Research Funding - Auris (Inst); Boston Scientific (Inst); Merit Medical Systems (Inst); Nuvaira (Inst); Olympus (Inst) |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Veracyte |
|
|
|
Stock and Other Ownership Interests - Veracyte |
|
|
|
Stock and Other Ownership Interests - Veracyte |
|
|
|
Stock and Other Ownership Interests - Veracyte |
|
|
|
Stock and Other Ownership Interests - Veracyte |
|
|
|
Stock and Other Ownership Interests - Veracyte |